Fasiglifam for glycaemic control in people with type 2 diabetes: A phase III, placebo-controlled study

Diabetes, Obesity and Metabolism

Volumn 19, Issue 12, 2017, Pages 1714-1721

  Marcinak, John ^a   Cao, Charles ^a   Lee, Douglas ^b   Ye, Zhan ^a  

^a TAKEDA DEVELOPMENT CENTER AMERICAS   (United States)

^b Takeda Global Research and Development Centre Europe   (United Kingdom)

Author keywords

antidiabetic drug; glycaemic control; phase III study; type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; FASIGLIFAM; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; ANTIDIABETIC AGENT; BENZOFURAN DERIVATIVE; FFAR1 PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SULFONE; TAK-875;

ABDOMINAL WALL HERNIA; ACUTE CHOLECYSTITIS; ACUTE KIDNEY FAILURE; ADULT; AGED; ANUS FISTULA; ARTHRALGIA; ARTICLE; BACKACHE; BODY MASS; CARDIOPULMONARY INSUFFICIENCY; CONTROLLED STUDY; DIARRHEA; DIET; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXERCISE; FEMALE; GLYCEMIC CONTROL; HEADACHE; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; WEIGHT CHANGE; AGONISTS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DIABETIC DIET; DRUG EFFECT; FOLLOW UP; LIVER; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OBESITY; PATHOPHYSIOLOGY; PATIENT DROPOUT; TOXIC HEPATITIS;

BENZOFURANS; BODY MASS INDEX; CHEMICAL AND DRUG INDUCED LIVER INJURY; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIET, DIABETIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXERCISE; FEMALE; FOLLOW-UP STUDIES; GLYCATED HEMOGLOBIN A; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; LIVER; LOST TO FOLLOW-UP; MALE; MIDDLE AGED; OBESITY; PATIENT DROPOUTS; RECEPTORS, G-PROTEIN-COUPLED; SULFONES;

EID: 85022343246     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13004     Document Type: Article

References (18)

1. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-591.
2. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005-2012.
3. Itoh Y, Kawamata Y, Harada M, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature. 2003;422(6928):173-176.
4. Edfalk S, Steneberg P, Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes. 2008;57(9):2280-2287.
5. Briscoe CP, Tadayyon M, Andrews JL, et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem. 2003;278(13):11303-11311.
6. Tsujihata Y, Ito R, Suzuki M, et al. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J Pharmacol Exp Ther. 2011;339(1):228-237.
7. Yashiro H, Tsujihata Y, Takeuchi K, Hazama M, Johnson PR, Rorsman P. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets. J Pharmacol Exp Ther. 2012;340(2):483-489.
8. Naik H, Vakilynejad M, Wu J, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol. 2012;52(7):1007-1016.
9. Leifke E, Naik H, Wu J, et al. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin Pharmcol Ther. 2012;92(1):29-39.
10. Burant CF, Viswanathan P, Marcinak J, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2012;379(9824):1403-1411.
11. Kaku K, Enya K, Nakaya R, Ohira T, Matsuno R. Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab. 2015;17(7):675-681.
12. Kaku K, Enya K, Nakaya R, Ohira T, Matsuno R. Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study. Diabetes Obes Metab. 2016;18(9):925-929.
13. Araki T, Hirayama M, Hiroi S, Kaku K. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14(3):271-278.
14. Kaku K, Araki T, Yoshinaka R. Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care. 2013;36(2):245-250.
15. Rockey DC, Seeff LB, Rochon J, et al; US Drug-Induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51(6):2117-2126.
16. Liu J, Wang Z, Ma Z, et al. Optimization of GPR40 agonists for type 2 diabetes. ACS Med Chem Lett. 2014;5(5):517-521.
17. Mancini AD, Poitout V. GPR40 agonists for the treatment of type 2 diabetes: life after “TAKing” a hit. Diabetes Obes Metab. 2015;17(7):622-629.
18. Wolenski FS, Zhu AZX, Johnson M, et al. Fasiglifam (TAK-875) alters bile acid homeostasis in rats and dogs: a potential cause of drug induced liver injury. Toxicol Sci. 2017;157(1):50-61.